Peter Ferenci

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection
    Ludwig Kramer
    Department of Medicine IV, Medical University Vienna, Austria
    AIDS 19:S85-92. 2005
  2. ncbi request reprint Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future
    P Ferenci
    Department of Internal Medicine IV, Medical University of Vienna, Vienna, Austria
    Minerva Gastroenterol Dietol 52:157-74. 2006
  3. ncbi request reprint Whom and how to screen for Wilson disease
    Peter Ferenci
    Department of Gastroenterology and Hepatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria 43 140 400 4945 43 140 400 4735
    Expert Rev Gastroenterol Hepatol 8:513-20. 2014
  4. doi request reprint Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow
    Peter Ferenci
    Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Best Pract Res Clin Gastroenterol 26:463-9. 2012
  5. doi request reprint Optimal treatment duration for patients with HCV genotype 1 infection
    P Ferenci
    Department of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    J Viral Hepat 19:7-13. 2012
  6. doi request reprint Treatment of chronic hepatitis C--are interferons really necessary?
    Peter Ferenci
    Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Liver Int 32:108-12. 2012
  7. pmc Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease
    Uta Merle
    Department of Gastroenterology and Hepatology, University Hospital, Heidelberg, Germany
    BMC Gastroenterol 10:8. 2010
  8. pmc Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients
    Peter Laszlo Lakatos
    1st Department of Medicine, Semmelweis University, Budapest, Hungary
    BMC Cancer 7:54. 2007
  9. ncbi request reprint Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection
    Peter Ferenci
    Department of Internal Medicine IV, Medical University, Vienna, Austria
    J Hepatol 44:275-82. 2006
  10. ncbi request reprint Wilson's Disease
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 3:726-33. 2005

Detail Information

Publications100

  1. ncbi request reprint Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection
    Ludwig Kramer
    Department of Medicine IV, Medical University Vienna, Austria
    AIDS 19:S85-92. 2005
    ..To assess the relative impact of fatigue and subclinical cognitive brain dysfunction on the impairment of health-related quality of life (HRQL) in hepatitis C virus (HCV) infection...
  2. ncbi request reprint Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future
    P Ferenci
    Department of Internal Medicine IV, Medical University of Vienna, Vienna, Austria
    Minerva Gastroenterol Dietol 52:157-74. 2006
    ..Although several promising oral agents have been identified and are currently in clinical development, it seems likely that pegylated interferon will remain the backbone of therapy for years to come...
  3. ncbi request reprint Whom and how to screen for Wilson disease
    Peter Ferenci
    Department of Gastroenterology and Hepatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria 43 140 400 4945 43 140 400 4735
    Expert Rev Gastroenterol Hepatol 8:513-20. 2014
    ..A diagnostic sum score of ≥4 confirms the diagnosis. ..
  4. doi request reprint Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow
    Peter Ferenci
    Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Best Pract Res Clin Gastroenterol 26:463-9. 2012
    ..Patients with eRVR can be cured by an abbreviated treatment regime. Further modification and unification of response criteria are needed for the currently evaluated interferon-free treatment regimes...
  5. doi request reprint Optimal treatment duration for patients with HCV genotype 1 infection
    P Ferenci
    Department of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    J Viral Hepat 19:7-13. 2012
    ..The recently described polymorphism in the region of the IL28B gene may help to select patients for abbreviated or extended treatment schedules...
  6. doi request reprint Treatment of chronic hepatitis C--are interferons really necessary?
    Peter Ferenci
    Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Liver Int 32:108-12. 2012
    ..Various other combinations are investigated currently. Providing that phase 3 studies will confirm these exciting data, direct acting antivirals or host targets will replace peginterferon/ribavirin combination therapy...
  7. pmc Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease
    Uta Merle
    Department of Gastroenterology and Hepatology, University Hospital, Heidelberg, Germany
    BMC Gastroenterol 10:8. 2010
    ..We aimed to evaluate whether 'severe' protein-truncating ATP7B mutations (SMs) are associated with low serum ceruloplasmin oxidase activities and an early age of onset when compared to missense mutations (MMs)...
  8. pmc Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients
    Peter Laszlo Lakatos
    1st Department of Medicine, Semmelweis University, Budapest, Hungary
    BMC Cancer 7:54. 2007
    ..Recently, NOD2/CARD15 has been associated with a risk for CRC in some studies, which stemmed from ethnically diverse populations. Our aim was to identify common NOD2/CARD15 mutations in Hungarian patients with sporadic CRC...
  9. ncbi request reprint Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection
    Peter Ferenci
    Department of Internal Medicine IV, Medical University, Vienna, Austria
    J Hepatol 44:275-82. 2006
    ..Using a novel design, amantadine was studied in naïve genotype 1 patients treated in combination with peginterferon alfa-2a (40KD)/ribavirin...
  10. ncbi request reprint Wilson's Disease
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 3:726-33. 2005
    ..Alternatively, haplotype analysis can be used to address diagnostic dilemmas in differentiating heterozygote gene carriers and affected asymptomatic siblings...
  11. doi request reprint Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Antivir Ther 16:1187-201. 2011
    ..Here, we review some of the complexities uncovered and controversies highlighted by the introduction of HCV protease inhibitors...
  12. doi request reprint Hepatitis: Treatment of chronic hepatitis C-how much interferon is enough?
    Peter Ferenci
    Medical University of Vienna, Internal Medicine III, Department of Gastroenterology and Hepatology, Waehringer Guertel 18 20, A1090 Vienna, Austria
    Nat Rev Gastroenterol Hepatol 7:191-3. 2010
    ..High-dose PEG-IFN induction therapy did not enhance early or sustained virologic response rates compared with standard of care therapy...
  13. ncbi request reprint Pathophysiology and clinical features of Wilson disease
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Metab Brain Dis 19:229-39. 2004
    ..Initial treatment for symptomatic patients should include a chelating agent (penicillamine or trientine). Treatment of presymptomatic patients or maintenance therapy can also be accomplished with zinc...
  14. ncbi request reprint Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  15. ncbi request reprint Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing
    Peter Ferenci
    Department of Internal Medicine IV, University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Hum Genet 120:151-9. 2006
    ..Knowledge of the differences in the worldwide distribution of particular mutations will help to design shortcuts for genetic diagnosis of WD...
  16. doi request reprint Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future
    Peter Ferenci
    Medical University of Vienna, Univ Klinik für Innere Medizin III, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Expert Opin Drug Saf 10:529-44. 2011
    ..Optimal patient management requires thorough knowledge of the adverse effect profiles of drugs used for this condition and strategies to mitigate these effects...
  17. ncbi request reprint Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Clin Gastroenterol Hepatol 3:811-8. 2005
    ..A 5-fold increase of hepatic copper concentration is considered as the best available test for diagnosis of hepatic Wilson's disease (WD). However, the sensitivity and specificity of this test have never been fully investigated...
  18. doi request reprint Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Gastroenterology 138:503-12, 512.e1. 2010
    ....
  19. ncbi request reprint Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s
    Peter Ferenci
    Department of Internal Medicine IV, Medical University of Vienna, Austria
    J Hepatol 47:31-6. 2007
    ..Data collected by a Foundation to help the victims enabled us to study the natural history of chronic hepatitis C in this cohort...
  20. doi request reprint Peginterferon and ribavirin in HCV: improvement of sustained viral response
    P Ferenci
    Univ Klinik für Innere Medizin III, Medical University of Vienna, AKH, Wien, Austria
    Best Pract Res Clin Gastroenterol 22:1109-22. 2008
    ..Treatment duration may be shortened in patients with undetectable HCV-RNA after 4 weeks of therapy, on the other hand slow virologic responders may benefit from prolonged treatment...
  21. doi request reprint Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy
    Peter Ferenci
    Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Gastroenterology 135:1561-7. 2008
    ..Oral Silibinin (SIL) is widely used for treatment of hepatitis C, but its efficacy is unclear. Substantially higher doses can be administered intravenously (IV)...
  22. ncbi request reprint Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy
    Petra Steindl-Munda
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Liver Int 23:269-75. 2003
    ..This prospective, randomized, controlled study tested whether non-responders or relapsers to interferon monotherapy also benefit from induction therapy...
  23. doi request reprint Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Gastroenterology 135:451-8. 2008
    ....
  24. doi request reprint Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection
    Sandra Beinhardt
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Gastroenterology 142:78-85.e2. 2012
    ..We associated IL28B SNPs rs12979860 and rs8099917, along with serum levels of IP-10, with outcomes of patients with acute hepatitis C (AHC)...
  25. doi request reprint Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy
    Karoline Rutter
    Department of Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Antivir Ther 16:1327-33. 2011
    ..In this proof-of-concept study, ivSIL was tested in on-treatment non-responders to full-dose of pegylated interferon-α2a/ribavirin (standard of care [SOC])...
  26. ncbi request reprint CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance
    Judith H Aberle
    Institute of Virology, Medical University of Vienna, Vienna, 1095, Austria
    J Infect Dis 195:1315-9. 2007
    ..The detectability of NS3-4--directed Th1 responses was associated with faster viremia clearance, was short-lived, and did not seem to be associated with the final treatment outcome...
  27. doi request reprint A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3
    Peter Ferenci
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Hepatology 47:1816-23. 2008
    ..4%-83.7%) in group B. Relapse rates in the 2 treatment groups were similar (17% in group A and 20% in group B). The incidence of adverse events, laboratory abnormalities, and dose reductions was similar in the 2 treatment groups...
  28. ncbi request reprint Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection
    Wolfgang Jessner
    Department of Internal Medicine III, Gastroenterology and Hepatology, Vienna Medical University, Vienna, Austria
    Antivir Ther 13:581-9. 2008
    ..Our aim was to investigate this approach in genotype 4 patients...
  29. doi request reprint Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin
    Thomas Matthias Scherzer
    Department of Internal Medicine III, Medical University, Vienna, Austria
    Hepatology 54:1518-26. 2011
    ..9% and 18.8%; P < 0.025, respectively) and in those with low (<400,000 IU/mL: 37.5% versus 18.8%) and high (≥ 400,000 IU/mL: 45.0% versus 18.8%) baseline viral loads...
  30. ncbi request reprint Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy
    Monika Homoncik
    Department of Internal Medicine IV, Division of Gastroenterology, Medical University Vienna, Vienna, Austria
    Am J Gastroenterol 101:2275-82. 2006
    ..Further, we hypothesize that EPO increases platelet reactivity and protease activated receptor 1 (PAR-1) expression during combination antiviral therapy...
  31. ncbi request reprint Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin
    Elisabeth Formann
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Am J Gastroenterol 99:873-7. 2004
    ..2 g ribavirin/d (COPEGUS, Roche, Nutley, USA) in de novo patients infected with HCV genotype 1. Sudden hearing loss and tinnitus developed on day 1 and after 4, 23, 25, 36, and 40 wk of treatment, respectively...
  32. doi request reprint Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection
    Thomas Reiberger
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 9:602-8.e1. 2011
    ..There are limited data on the efficacy and safety of antiviral therapy in patients with hepatitis C virus (HCV)-related cirrhosis, particularly on the impact of portal hypertension...
  33. doi request reprint A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis
    Monika Schmid
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Liver Int 30:574-82. 2010
    ..Several treatments have been introduced but only L-ornithine-L-aspartate (LOLA) shows proven efficacy. This double-blind, randomized, placebo-controlled trial evaluated the effect of LOLA on postural control in cirrhotics...
  34. doi request reprint Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C
    Albert Friedrich Stättermayer
    Division for Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    J Hepatol 57:492-8. 2012
    ..The aim of our study was to evaluate the role of these polymorphisms on insulin resistance (IR) in treatment-naïve patients with chronic hepatitis C...
  35. ncbi request reprint Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia
    Harald Hofer
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 118:595-600. 2006
    ..We evaluated the safety, efficacy and tolerability of standard interferon-alpha in an accelerating dose regimen in combination with ribavirin in patients with HCV-induced liver cirrhosis and thrombocytopenia...
  36. ncbi request reprint Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a
    Harald Hofer
    Department of Internal Medicine IV, University of Vienna, Austria
    Am J Gastroenterol 97:2880-5. 2002
    ..Furthermore, the effect of hepatitis C virus (HCV) eradication by antiviral therapy on serum cholesterol levels was studied...
  37. doi request reprint Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C
    Albert Friedrich Stättermayer
    Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 9:344-350.e2. 2011
    ..We investigated the roles of polymorphisms rs12979860 and rs8099917 on the early virologic response of treatment-naïve patients...
  38. ncbi request reprint Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C
    Harald Hofer
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Waehringerguertel 18 20, A 1090 Vienna, Austria
    J Hepatol 40:1018-22. 2004
    ..In this study the role of hepatic iron concentration (HIC) and serum iron parameters was assessed to determine response to standard and pegylated interferon (IFN)/ribavirin combination therapy in patients with CHC...
  39. doi request reprint Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin
    Thomas Matthias Scherzer
    Medical University of Vienna, Internal Medicine III, Department of Gastroenterology and Hepatology, Austria
    J Hepatol 54:866-71. 2011
    ..This study analyzes the impact of these IL28B polymorphisms on early treatment response (weeks 2 and 4) and SVR in HCV genotype 3 patients...
  40. ncbi request reprint TGF-beta1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis
    Christoph H Osterreicher
    Department of Internal Medicine IV, Medical University of Vienna, Austria
    Cytokine 31:142-8. 2005
    ..8 (95% CI 1.4-5.7, p = 0.004). In conclusion, C282Y homozygotes carrying TGF-beta1 genotypes Arg/Pro and Pro/Pro are more likely to develop cirrhosis than those with genotype Arg/Arg...
  41. ncbi request reprint Mutations of the HFE gene in patients with hepatocellular carcinoma
    Edmund Cauza
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Am J Gastroenterol 98:442-7. 2003
    ..Patients with genetic hemochromatosis may be at risk for HCC, but limited information is available on the relationship of HCC and heterozygosity for the HFE gene mutations...
  42. ncbi request reprint Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis
    Christoph H Osterreicher
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Wien, Austria
    J Hepatol 42:914-9. 2005
    ..This study assessed the impact of polymorphisms of the MPO (-463G/A) and the HO-1 promotors of Vienna (GT)n on the evolution of cirrhosis in patients with HHC...
  43. doi request reprint Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful?
    Lili Kazemi-Shirazi
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 120:25-30. 2008
    ..Specific markers for differentiation of nonalcoholic (NASH) from alcoholic steatohepatitis (ASH) are lacking. We investigated the role of routine laboratory parameters in distinguishing NASH from ASH...
  44. ncbi request reprint Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C
    Calin Gurguta
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Am J Gastroenterol 101:197-8. 2006
    ....
  45. ncbi request reprint Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C
    Wolfgang Sieghart
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Thromb Haemost 95:260-6. 2006
    ..This does not result in an alteration of global platelet function as assessed by the PFA-100, because elevated vWF-Antigen levels might compensate for the acquired defect...
  46. doi request reprint IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients
    Berit A Payer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 42:599-606. 2012
    ..The predictive value of interferon-gamma inducible protein 10 (IP10) on treatment outcome has been described in HCV patients. Data on combining these predictors in HIV-HCV-coinfected patients are not available...
  47. ncbi request reprint Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial
    Christian Muller
    Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Medical University of Vienna, Austria
    Wien Klin Wochenschr 120:608-18. 2008
    ..The aim of the study was to compare the clinical outcome of additional percutaneous ethanol instillation (PEI) against no further treatment in patients with hepatocellular carcinoma receiving hormonal treatment with long-acting octreotide...
  48. ncbi request reprint Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load
    Harald Hofer
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    Hepatology 37:60-4. 2003
    ..IFN therapy appears only needed in patients who fail to clear the virus within 35 days after onset of symptoms. By this approach, IFN therapy was not necessary in two thirds of patients with acute hepatitis C...
  49. doi request reprint Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus
    Sandra Beinhardt
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Clin Infect Dis 56:118-22. 2013
    ..Based on viral kinetics, an even earlier prediction after 2 weeks of treatment with direct acting antivirals appears feasible...
  50. doi request reprint Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?
    Sandra Beinhardt
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Hepatology 55:30-8. 2012
    ..If analyzed according to the IL28B polymorphism, TPP SVR rates did not reach statistically significant differences among study and SOC patients...
  51. ncbi request reprint Late-onset Wilson's disease
    Peter Ferenci
    Department of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Gastroenterology 132:1294-8. 2007
    ..The clinical symptoms and age at onset of Wilson's disease (WD) are highly variable. This study investigated patients who became symptomatic at >40 years of age...
  52. doi request reprint Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy
    Harald Hofer
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Waehringerguertel 18 20, Vienna, Austria
    J Hepatol 52:812-6. 2010
    ..The aim of this study was to evaluate seminal parameters and ribavirin and HCV-RNA concentrations in seminal fluid and serum prior to and during antiviral treatment...
  53. ncbi request reprint Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Antimicrob Chemother 53:15-8. 2004
    ..Patients who become HCV-RNA negative after 4 weeks have the best chance of achieving an SVR. The rapidity of viral elimination may be a useful guide to tailoring the length of treatment in patients with an EVR...
  54. ncbi request reprint Increased C282Y heterozygosity in gestational diabetes
    Edmund Cauza
    Department of Internal Medicine V, Wilhelminenspital, Vienna, Austria
    Fetal Diagn Ther 20:349-54. 2005
    ....
  55. ncbi request reprint Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha
    Markus Peck-Radosavljevic
    Department of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Gastroenterology 123:141-51. 2002
    ..Treatment of chronic hepatitis C with interferon (IFN)-alpha often has hematotoxic effects. We evaluated the effects of acute vs. chronic and standard vs. pegylated IFN-alpha on hematopoiesis...
  56. ncbi request reprint Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection
    Judith H Aberle
    Institute of Virology, Medical University of Vienna, Austria
    J Clin Virol 36:24-31. 2006
    ..The outcome of acute hepatitis C is determined by early host-virus interactions, particularly involving the antiviral T-cell response...
  57. doi request reprint Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients
    Thomas Matthias Scherzer
    Department of Internal Medicine III, Medical University, Vienna, Austria
    J Hepatol 59:964-71. 2013
    ..To investigate other possible protective cofactors, gender differences were analyzed in patients with HCV genotype 1...
  58. doi request reprint Long-term outcomes of patients with Wilson disease in a large Austrian cohort
    Sandra Beinhardt
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University Vienna, Austria
    Clin Gastroenterol Hepatol 12:683-9. 2014
    ..There are few data on long-term outcomes and survival from large cohorts; we studied these features in a well-characterized Austrian cohort of patients with Wilson disease...
  59. doi request reprint A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection
    Sandra Beinhardt
    Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    J Hepatol 59:972-7. 2013
    ..The aim of this study was to define a score enabling the discrimination of patients with spontaneous clearance of HCV from those with development of viral persistence and need for early antiviral treatment...
  60. ncbi request reprint Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis
    Maximilian Schoniger-Hekele
    Universitatsklinik fur Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria
    Dig Dis Sci 47:1909-14. 2002
    ..Our data suggest that microchimerism does not play a significant role in the development of PBC...
  61. doi request reprint Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study
    Harald Hofer
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    J Hum Genet 57:564-7. 2012
    ..None of the 100 healthy controls carried the mutation. We describe a novel mutation in the ATP7B gene, occurring in patients originated from a distinct geographical area in Austria associated with a variable course of the disease...
  62. ncbi request reprint Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia
    Simon Panzer
    Clinic for Blood Group Serology, Medical University Vienna, Vienna, Austria
    Eur J Haematol 77:513-7. 2006
    ....
  63. doi request reprint Severity of organ failure is an independent predictor of intracranial hypertension in acute liver failure
    Reinhard Kitzberger
    Department of Gastroenterology, Hepatology and Medical Intensive Care Medicine, Medical University Hospital Vienna, Vienna, Austria
    Clin Gastroenterol Hepatol 7:1000-6. 2009
    ..We investigated whether the severity of organ failure was associated with intracranial hypertension and evaluated the correlation between NH(3) and pNH(3) and grade of hepatic encephalopathy...
  64. doi request reprint Clinical impact of arterial ammonia levels in ICU patients with different liver diseases
    Andreas Drolz
    Intensive Care Unit 13H1, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Intensive Care Med 39:1227-37. 2013
    ..Data on the prognostic impact of arterial ammonia is lacking in hypoxic hepatitis (HH) and scarce in critically ill patients with cirrhosis...
  65. pmc Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial
    Andreas Maieron
    Gastroenterology and Hepatology, Elisabethinen Hospital, Fadingerstrasse 1, Linz, 4020, Austria
    BMC Res Notes 4:220. 2011
    ..abstract:..
  66. ncbi request reprint Liver pathology in compound heterozygous patients for hemochromatosis mutations
    Maximilian Schoniger-Hekele
    Universitatsklinik fur Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria
    Liver 22:295-301. 2002
    ..While hepatic pathology of homozygous carriers of the C282Y mutation of the HFE haemochromatosis gene is well defined, the impact of the C282Y/H63D compound heterozygous carrier state is unknown...
  67. ncbi request reprint Predictors of response to therapy for chronic hepatitis C
    Peter Ferenci
    Professor of Medicine, Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Semin Liver Dis 24:25-31. 2004
    ..This article reviews the various patient and viral factors that help predict response to various interferon-based therapies, ranging from interferon alone to the new pegylated interferons...
  68. ncbi request reprint Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma
    Walter Reinisch
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Immunother 25:489-99. 2002
    ..Immunotherapeutic approaches hold promise to prolong survival in selected patients with advanced HCC who respond by enhanced tumor immunogenicity...
  69. ncbi request reprint Hepatitis C viral dynamics: basic concept and clinical significance
    Wolfgang Jessner
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University Hospital, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Virol 25:S31-9. 2002
    ..Furthermore, limitations of currently available quantitative assays will be discussed...
  70. doi request reprint Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy
    Martin Krssak
    Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Austria
    Eur J Radiol 74:e60-6. 2010
    ..Liver biopsy is the standard method for diagnosis of hepatic steatosis, but is invasive and carries some risk of morbidity...
  71. ncbi request reprint Subclinical impairment of brain function in chronic hepatitis C infection
    Ludwig Kramer
    Department of Medicine IV, University Hospital Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    J Hepatol 37:349-54. 2002
    ..This study tested the hypothesis of a subclinical cognitive dysfunction in HCV-infected patients...
  72. doi request reprint [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]
    Markus Peck-Radosavljevic
    Osterreichische Gesellschaft für Gastroenterologie und Hepatologie, Arbeitsgruppe Leber, Wien, Austria
    Wien Klin Wochenschr 122:280-302. 2010
    ..Overall this consensus statement accounts for the major advances in the management of hepatitis B and significantly changes clinical management of patients with hepatitis B in Austria...
  73. ncbi request reprint Wilson disease
    Reinhard Kitzberger
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090, Vienna, Austria
    Metab Brain Dis 20:295-302. 2005
    ..Presence of liver disease, neurologic symptoms, and Kayser-Fleischer corneal rings are the hallmarks of the disease...
  74. ncbi request reprint Paraneoplastic pemphigus in association with hepatocellular carcinoma
    Gabriele Hinterhuber
    Department of Dermatology, School of Medicine, University of Vienna, Austria
    J Am Acad Dermatol 49:538-40. 2003
    ..This patient met all diagnostic criteria for paraneoplastic pemphigus and is, to our knowledge, the first report of a case associated with hepatocellular carcinoma...
  75. ncbi request reprint Transjugular intrahepatic portosystemic shunt in Vienna--a decade later
    Bernhard Angermayr
    Department of Internal Medicine IV, University of Vienna, Vienna, Austria
    Wien Klin Wochenschr 116:608-13. 2004
    ....
  76. ncbi request reprint Treatment of chronic viral hepatitis
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Wahringer Gurtel 18 20, Wien A 1090, Austria
    Best Pract Res Clin Gastroenterol 18:113-20. 2004
    ..No adefovir-associated resistance mutations of viral DNA were detected. Ongoing studies investigate combination therapy with lamivudine or IFN...
  77. doi request reprint Evolution of Crohn's disease-associated Nod2 mutations
    Christoph Gasche
    Department of Medicine 3, Medical University of Vienna, Vienna, Austria
    Immunogenetics 60:115-20. 2008
    ..As mutations in exons 4e, 8, and 12 were only found in association with SNP5, this variant may have allowed selection pressure to arise...
  78. doi request reprint Comparison of alcohol-dependent patients at a gastroenterological and a psychiatric ward according to the Lesch alcoholism typology: implications for treatment
    Benjamin Vyssoki
    Department of Psychiatry and Psychotherapy, Medical University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    Alcohol Alcohol 45:534-40. 2010
    ....
  79. ncbi request reprint Hepatic transport systems
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Austria
    J Gastroenterol Hepatol 17:S105-12. 2002
    ..Beyond these well defined diseases, functional impairments of transport proteins may predispose to non-genetic diseases ranging from intrahepatic cholestasis of pregnancy to neurodegenerative disorders including Alzheimer's disease...
  80. ncbi request reprint Dysfunction of the liver affects the sense of smell
    Andreas F P Temmel
    Department of Otorhinolaryngology, University of Vienna, AKH Wien, Vienna, Austria
    Wien Klin Wochenschr 117:26-30. 2005
    ....
  81. ncbi request reprint Infliximab: lack of efficacy on perforating complications in Crohn's disease
    Wolfgang Miehsler
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Inflamm Bowel Dis 10:36-40. 2004
    ..However, little knowledge exists about its use for the treatment of internal fistulas in CD. We present our experience with infliximab in this situation...
  82. ncbi request reprint Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998
    Peter Ferenci
    Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Hepatology 35:716-21. 2002
    ..Finally, the need for a careful evaluation of the newer neuroimaging modalities for the diagnosis of hepatic encephalopathy was stressed...
  83. ncbi request reprint Diagnosis and phenotypic classification of Wilson disease
    Peter Ferenci
    University of Vienna, Austria
    Liver Int 23:139-42. 2003
    ..After the meeting, a preliminary draft of a consensus report was mailed to all active participants and their comments were incorporated in the final text...
  84. ncbi request reprint Sonographic diagnosis of coeliac disease in a case with suspected acute liver failure
    Barbara Schmidt
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Eur J Gastroenterol Hepatol 17:995-8. 2005
    ..This case report suggests that coeliac disease should also be considered in patients with unexplained severe acute liver disease and that abdominal ultrasound may be a helpful step to obtain to the correct diagnosis...
  85. ncbi request reprint Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis
    Thomas Watkins-Riedel
    Division of Clinical Virology, Institute of Virology, University Hospital of Vienna, Austria
    Clin Infect Dis 39:1754-60. 2004
    ..Analysis of whole-blood specimens for detection of viral RNA should provide more-accurate prognostic information...
  86. ncbi request reprint Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials
    Naga Chalasani
    Indiana University Medical Center, Indianapolis, USA
    Hepatology 41:289-98. 2005
    ..Randomized controlled studies are needed to establish the efficacy of pegylated interferon and ribavirin in patients who have undergone OLT...
  87. ncbi request reprint Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations
    Peter Laszlo Lakatos
    1st Department of Medicine, Semmelweis University, Koranyi str 2 A, H 1083, Hungary
    World J Gastroenterol 11:1489-95. 2005
    ..To determine common NOD2/CARD15 mutations and TLR4 D299G polymorphism in Hungarian patients with CD...
  88. ncbi request reprint Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a
    Peter Ferenci
    Am J Gastroenterol 100:1626-7. 2005
  89. ncbi request reprint Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C
    Wolfgang Jessner
    Hepatology 36:1301-2. 2002
  90. ncbi request reprint Common mutations of ATP7B in Wilson disease patients from Hungary
    Gabor Firneisz
    1st Department of Medicine, Semmelweis University, Budapest, Hungary
    Am J Med Genet 108:23-8. 2002
    ..The H1069Q point mutation is frequent in Hungarian patients with WD and appears to have originated from a single founder in Eastern Europe. In contrast, mutations in exons 8, 13, 15, and 18 are uncommon in Hungarian WD patients...
  91. ncbi request reprint Depression in chronic hepatitis: the virus, the drug, or the ethnic background?
    Peter Ferenci
    Liver Int 28:429-31. 2008
  92. ncbi request reprint Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children
    Thomas Muller
    Department of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria
    J Hepatol 47:270-6. 2007
    ..2% and sensitivity of 88.2% in diagnosing Wilson's disease (WD). We have re-evaluated this test. Ninety-eight subjects were studied at presentation...
  93. ncbi request reprint Novel mutations of the ATP7B gene among 109 Hungarian patients with Wilson's disease
    Aniko Folhoffer
    First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
    Eur J Gastroenterol Hepatol 19:105-11. 2007
    ..The aim of the present study was to assess the impact of genetic testing for diagnosis of the disease in a large cohort (n=109) from Hungary...
  94. ncbi request reprint Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4
    Samuel S Lee
    Liver Unit, University of Calgary, Calgary, Alberta, Canada
    Antivir Ther 13:9-16. 2008
    ..Here, we discuss the importance of baseline predictors of response and the emerging concept of response-guided therapy in genotype 1 and 4 patients...
  95. ncbi request reprint Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
    Donald M Jensen
    Center for Liver Diseasees, University of Chicago Hospitals, 60637, USA
    Hepatology 43:954-60. 2006
    ..In conclusion, patients infected with HCV genotype 1 and treated with peginterferon alpha-2a/ribavirin sustained a RVR 24% of the time. This portends an 89% probability of a SVR after 24 weeks of treatment...
  96. ncbi request reprint Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    Stefan Zeuzem
    Clinic of Internal Medicine II, Department of Medicine, Saarland University Hospital, Kirrbergerstrasse, 66421 Homburg Saar, Germany
    J Hepatol 44:97-103. 2006
    ..The aim of the present study was to investigate this schedule in the era of pegylated interferon-alpha plus ribavirin...
  97. ncbi request reprint Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis
    Felix Stickel
    Department of Medicine I, University of Erlangen Nurnberg, Erlangen, Germany
    Arch Intern Med 165:1835-40. 2005
    ..Our objective was to establish the role of the functional polymorphisms of GSTP1 (codon 105 Ile-->Val) and MnSOD (codon 16 of precursor protein Ala-->Val) on the evolution of cirrhosis in patients with HHC and CHC...
  98. ncbi request reprint The host or the virus? Impact of genetic factors on the outcome of hepatitis C virus infection
    Peter Ferenci
    Gastroenterology 131:954-6. 2006
  99. ncbi request reprint Copper toxicosis gene MURR1 is not changed in Wilson disease patients with normal blood ceruloplasmin levels
    Karl Heinz Weiss
    Department of Gastroenterology, University of Heidelberg, Germany
    World J Gastroenterol 12:2239-42. 2006
    ..To analyze our Wilson disease patient cohort (n=106) for alterations in the gene coding for MURR1...
  100. ncbi request reprint The other mutation is found: follow-up of an exceptional family with Wilson disease
    Gabor Firneisz
    Am J Gastroenterol 99:2504-5. 2004